Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Transcatheter Tricuspid Valve Interventions in the TAVR Population
Author(s): Molly Silkowski , Payton Kendsersky , Nicholas Amoroso Added: 1 year ago

Intervention
TCT 24: The TRISCEND II Trial
Author(s): Susheel Kodali Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).TRISCEND II is a… View more

Intervention
Device Therapies in Heart Failure
Author(s): Yoel Benarroch , Natalie Tapaskar , Amin Yehya Added: 8 months ago

Intervention

Heart Failure
Managing LVOT Obstruction in Transcatheter Mitral Replacement with Dr Eleid
Author(s): Mackram F Eleid Added: 7 months ago
Explore advanced strategies for preventing and managing LVOT obstruction in transcatheter mitral valve replacement with Dr Mackram EleidThis presentation, part of Women As One's comprehensive Structural Interventions track, examines of a 90-year-old patient with severe mitral annular calcification, heart failure with preserved ejection fraction, and significant basal septal hypertrophy. Dr Eleid… View more

Intervention
AHA 25: Beta-Blocker Therapy Post MI in Patients with Preserved LVEF
Author(s): Anna Meta Dyrvig Kristensen Added: 7 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled… View more

Heart Failure
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 7 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses… View more

Prevention & Chronic Conditions
Novel Therapies in ATTR-CM
Author(s): Michelle Dimza , Georgia Vasilakis , Justin L Grodin Added: 7 months ago

Heart Failure
ESC 25: Lifetime Benefits of Combination Therapy in HFpEF
Author(s): Muthiah Vaduganathan Added: 9 months ago
ESC Congress 2025 - Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, Boston, US) joins us to discuss findings from a trial investigating the lifetime benefits of combination therapy for patients with HFpEF by looking at individual level data from DELIVER, FINEARTS-HF and PARAGON-HF trials.Interview Questions:1. What is the reasoning behind the trial?2. What was the study design and patient… View more

Heart Failure
Definitions and Implications of Shock Diagnosis and Therapy with Dr Frederick Welt
Author(s): Frederick Welt Added: 8 months ago
Learn about the definition and implications of a shock diagnosis and systems of care and the role of the shock team from Dr Frederick Welt (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick… View more

Intervention

MI/ACS
TCT 24: The TAVR UNLOAD Trial
Author(s): Nicolas M Van Mieghem Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)… View more

Intervention